Hap Trading, LLC Curis Inc Call Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $10,857 - $397,782	-23,100 Reduced 64.35%	12,800 $0
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $13,024 - $264,176	17,600 Added 96.17%	35,900 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.71 - $2.43 $3,266 - $11,178	4,600 Added 33.58%	18,300 $2,000
Q1 2022 May 12, 2022	BUY	$2.31 - $5.13 $31,647 - $70,281	13,700 New	13,700 $2,000
Q4 2021 Feb 14, 2022	SELL	$4.45 - $8.09 $191,350 - $347,870	-43,000 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$6.94 - $8.85 $64,542 - $82,305	-9,300 Reduced 17.78%	43,000 $14,000
Q2 2021 Aug 11, 2021	BUY	$7.45 - $16.27 $282,355 - $616,633	37,900 Added 263.19%	52,300 $38,000
Q1 2021 May 14, 2021	SELL	$8.78 - $12.8 $14,925 - $21,760	-1,700 Reduced 10.56%	14,400 $27,000
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $17,388 - $132,020	16,100 New	16,100 $43,000
Q3 2020 Nov 13, 2020	SELL	$0.95 - $1.42 $16,245 - $24,282	-17,100 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$0.63 - $1.7 $10,773 - $29,070	17,100 New	17,100 $1,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.